Pain Drug Development Pipeline Review, 2018
- Pages: 148
- Published: September 2018
- Report Code: GBIHC047IDB
This report provides an overview of the pipeline landscape for pain disorders. It provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for post-operative pain, fibromyalgia, complex regional pain syndrome (CRPS) and visceral pain, and features dormant and discontinued products.
Pain is one of the main post-operative adverse outcomes causing distress to patients. Causes of post-operative pain include peripheral nerve damage during surgery, inflammation at the site of the wound and damage to bodily tissues during surgery. Risk factors include site of the operation, age, level of fear or anxiety, surgical procedure, personal preference and response to agents given. Treatment for post-operative pain includes analgesia and anesthetics. There are 74 products in development for this indication.
Fibromyalgia is a disorder characterized by widespread musculoskeletal pain accompanied by fatigue, sleep, memory and mood issues. Symptoms include fatigue, depression, headaches, and pain or cramping in the lower abdomen. The predisposing factors include family history, rheumatoid arthritis or lupus. Treatment includes pain relievers, antidepressants and anti-seizure drugs. There are 21 products in development for this indication.
CRPS is a chronic pain condition that most often affects one limb, usually after an injury. CRPS is divided into two types: CRPS-I (individuals without a confirmed nerve injury) and CRPS-II (when there is an associated, confirmed nerve injury). Symptoms include stiffness in the affected joints, changes in nail and hair growth patterns, dystonia and abnormal sweating pattern. Treatment includes bisphosphonates, non-steroidal anti-inflammatory drugs, opioids and local anesthetic creams. There are seven products in development for this indication.
Visceral pain is a type of nociceptive pain that comes from the internal organs. Symptoms include aches, cramps and diffuse pain. Treatment includes analgesics such as narcotics or nonsteroidal anti-inflammatory drugs and pain modifiers such as tricyclic antidepressants or anticonvulsants. There are 38 products in development for this indication.
Molecular targets acted on by products in development for pain disorders include beta nerve growth factor, cannabinoid receptors, opioid receptors and protein kinases. Companies operating in this pipeline space include NeurAxon, Abide Therapeutics and Pfizer.
Scope
– Which companies are the most active within each pipeline?
– Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
– To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
– What are the most important R&D milestones and data publications to have happened in this disease area?
Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration
Companies mentioned
Abide Therapeutics Inc
Abiogen Pharma SpA
AcelRx Pharmaceuticals Inc
Addex Therapeutics Ltd
Adynxx Inc
Anavex Life Sciences Corp
AngioChem Inc
Aoxing Pharmaceutical Company Inc
Apsen Farmaceutica SA
Aptinyx Inc
Arena Pharmaceuticals Inc
Artelo Biosciences Inc
Astellas Pharma Inc
Cadila Healthcare Ltd
Camurus AB
Cara Therapeutics Inc
Center Laboratories Inc
CerSci Therapeutics Inc
Chromocell Corp
Colby Pharmaceutical Co
Daiichi Sankyo Co Ltd
Dompe Farmaceutici SpA
Echo Pharmaceuticals BV
Eisai Co Ltd
Eli Lilly and Co
Eupraxia Pharmaceuticals Inc
EyeGate Pharmaceuticals Inc
Fujimoto Pharmaceutical Corp
Grunenthal GmbH
GW Pharmaceuticals Plc
Heron Therapeutics Inc
Idera Pharmaceuticals Inc
Immupharma Plc
Innocoll AG
Innovative Med Concepts LLC
Insys Therapeutics Inc
Intec Pharma Ltd
Ionis Pharmaceuticals Inc
Ironwood Pharmaceuticals Inc
iX Biopharma Ltd
Jiangsu Hengrui Medicine Co Ltd
Kyorin Pharmaceutical Co Ltd
Kytogenics Pharmaceuticals Inc
Lipella Pharmaceuticals Inc
Lipocure Ltd
Liquidia Technologies Inc
Lumosa Therapeutics Co Ltd
Luye Pharma Group Ltd
Medtronic Plc
Merck & Co Inc
Mundipharma International Ltd
Neumentum Inc
Novartis AG
Ocular Therapeutix Inc
Pacira Pharmaceuticals Inc
PainReform Ltd
Pfizer Inc
Pharmaleads SA
PhytoHealth Corp
Piramal Enterprises Ltd
PixarBio Corp
PolyPid Ltd
Prismic Pharmaceuticals Inc
RaQualia Pharma Inc
Recro Pharma Inc
Serina Therapeutics Inc
SteadyMed Therapeutics Inc
Taiwan Liposome Company Ltd
Teikoku Pharma USA Inc
Tetra Bio-Pharma Inc
Trevena Inc
UCB SA
Urigen Pharmaceuticals Inc
Virpax Pharmaceuticals Inc
Vitality Biopharma Inc
Xigen SA
YiChang Humanwell Pharmaceutical Co Ltd
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple purchases.